Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NSCLC
Biotech
Verastem CEO says RAS drug 'set new benchmark' for tricky cancer
Verastem Oncology's decision to refocus its R&D efforts on its KRAS inhibitor appears to be paying off based on initial data from a phase 1/2 trial.
Marissa Russo
Oct 14, 2026 10:27am
AstraZeneca's ph. 3 cancer fail is latest blow to ATR inhibitors
Dec 22, 2025 4:35am
Bayer picks Kumquat for $1.3B KRAS collaboration
Aug 12, 2025 6:29am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
Boehringer flexes staying power of HER2-mutant lung cancer med
Apr 28, 2025 9:00am
iTeos drops one of 3 clinical assets from pipeline
Dec 12, 2024 3:10pm
